Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
- Contraceptive Devices, Female
- Contraceptive Agents, Female
- intrauterine devices
- intrauterine devices, copper
- Intrauterine devices, Medicated
- long-acting reversible contraception
The Faculty of Sexual & Reproductive Healthcare (FSRH) Clinical Effectiveness Unit (CEU) has recently published an updated intrauterine device (IUD) guideline, incorporating new evidence-based recommendations alongside refreshed established guidance.1
IUDs are effective and popular long-acting reversible contraception (LARC) used by approximately 159 million users worldwide2 and by approximately 21% of individuals seeking contraception at sexual health services in England.3
Indications and duration of use of the levonorgestrel IUD
With the addition of Benilexa® to the market in 2021, there are now three 52 mg levonorgestrel IUDs (LNG-IUDs) available in the UK. While the licensed durations and indications of use differ between the 52 mg LNG-IUDs, the FSRH Guideline Development Group advocate that the similarity between the devices and levonorgestrel (LNG) release rates is sufficient to extrapolate evidence from one device to another (table 1).
Although Mirena® is the only LNG-IUD licensed for endometrial protection as part of hormone replacement therapy (HRT), this guideline recommends that any 52 mg LNG-IUD can be used as endometrial protection for 5 years .
Duration of use
Similarly, as Levosert® and Benilexa are licensed for use for 6 years for contraception (Mirena is licensed for 5 years), this guideline recommends that any 52 mg LNG-IUD inserted before age 45 years can be used for contraception for 6 years .
In individuals aged …
Contributors AJ drafted the manuscript. KB reviewed and edited the manuscript.
Both AJ and KB reviewed and edited following peer review for the revised version.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests KB led the Guideline Development Group for the FSRH updated Intrauterine Contraception guideline. KB is the Co-director of the Clinical Effectiveness Unit of the FSRH.
Provenance and peer review Not commissioned; internally peer reviewed.